A case report: antiviral triple therapy with telaprevir in a haemodialysed HCV patient in Turkey

A 49-year-old woman was diagnosed with chronic hepatitis C 7 years ago. She began haemodialysis at the same time. She was on the waiting list for kidney transplantation (KTx). The real-time PCR technique revealed an HCV RNA viral load of 212 000 IU/ml, genotype 1a, IL28B the rs12979860 minor allele heterozygous CT (rs8099917 TT homozygous). She had a history of first antiviral treatment for 48 weeks of PEG-IFN-alpha 2a, 135 mu g/week in 2011, but the HCV infection relapsed. Considering her relatively young age, candidacy for renal transplant, and the heterozygous pattern of IL28B, we decided to proceed with a second (and last) antiviral treatment using triple therapy with telaprevir at the regular dose of 750 mg every 8 hours + PEG-IFN-alpha 2a 135 mg/week sc + 200 mg RBV three times a week. At the end of 6-month therapy, HCV RNA was found to be negative at months 3, 5, and 6. The patient has reached the sustained virological response (SVR) and is ready for KTx. All renal transplant candidates (dialysis-dependent, or not) with HCV should be assessed for antiviral treatment given the increased risk of progressive liver disease due to immunosuppressive therapy, increased life expectancy compared to other HCV-positive patients on dialysis, and the inability to receive interferon after transplantation.

Yazar Akhan, S.
Sayan, M.
Altunok, E. Sargin
Aynioglu, A.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/1932
Tek Biçim Adres 10.1179/2295333715Y.0000000046
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı ACTA CLINICA BELGICA
Dergi Cilt Bilgisi 70
Dergi Sayısı 6
Sayfalar 440 - 441
Yayın Yılı 2015
Eser Adı
[dc.title]
A case report: antiviral triple therapy with telaprevir in a haemodialysed HCV patient in Turkey
Yazar
[dc.contributor.author]
Akhan, S.
Yazar
[dc.contributor.author]
Sayan, M.
Yazar
[dc.contributor.author]
Altunok, E. Sargin
Yazar
[dc.contributor.author]
Aynioglu, A.
Yayın Yılı
[dc.date.issued]
2015
Yayıncı
[dc.publisher]
MANEY PUBLISHING
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
A 49-year-old woman was diagnosed with chronic hepatitis C 7 years ago. She began haemodialysis at the same time. She was on the waiting list for kidney transplantation (KTx). The real-time PCR technique revealed an HCV RNA viral load of 212 000 IU/ml, genotype 1a, IL28B the rs12979860 minor allele heterozygous CT (rs8099917 TT homozygous). She had a history of first antiviral treatment for 48 weeks of PEG-IFN-alpha 2a, 135 mu g/week in 2011, but the HCV infection relapsed. Considering her relatively young age, candidacy for renal transplant, and the heterozygous pattern of IL28B, we decided to proceed with a second (and last) antiviral treatment using triple therapy with telaprevir at the regular dose of 750 mg every 8 hours + PEG-IFN-alpha 2a 135 mg/week sc + 200 mg RBV three times a week. At the end of 6-month therapy, HCV RNA was found to be negative at months 3, 5, and 6. The patient has reached the sustained virological response (SVR) and is ready for KTx. All renal transplant candidates (dialysis-dependent, or not) with HCV should be assessed for antiviral treatment given the increased risk of progressive liver disease due to immunosuppressive therapy, increased life expectancy compared to other HCV-positive patients on dialysis, and the inability to receive interferon after transplantation.
Açıklama
[dc.description]
WOS: 000369185300011
Açıklama
[dc.description]
PubMed: 26790555
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1784-3286
ISSN
[dc.identifier.issn]
2295-3337
İlk Sayfa Sayısı
[dc.identifier.startpage]
440
Son Sayfa Sayısı
[dc.identifier.endpage]
441
Dergi Adı
[dc.relation.journal]
ACTA CLINICA BELGICA
Dergi Sayısı
[dc.identifier.issue]
6
Dergi Cilt Bilgisi
[dc.identifier.volume]
70
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1179/2295333715Y.0000000046
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/1932
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
63
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
14 Temmuz 2024 10:27
Google Kontrol
Tıklayınız
antiviral treatment therapy transplantation increased 2a PEG-IFN-alpha transplant heterozygous months negative 6-month mg/week regular patient disease immunosuppressive expectancy compared HCV-positive progressive patients dialysis inability receive interferon reached sustained virological response candidates (dialysis-dependent should assessed telaprevir
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms